glp-1 drug news Overdoses Are on the Rise: What You Need to Know GLP-1 Agonists Weight Loss Drugs

Quality Standards & Traceability

We also describe the development of incretin-based pharmacotherapy, starting with exendin- 4 and ending with the identification of multi-incretin hormone receptor agonists, which appear to be the next major step in the fight against T2DM and obesity

This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient

Similarly, the American Association of Clinical Endocrinology introduced its Adiposity-Based Chronic Disease model, replacing BMI-centric classification with a staging system based on obesity-related complications [4]

Learn what patients and prescribers should know about lean mass, protein, and exercise.

Clinical trial data shows a 5-10 BPM increase driven by the glucagon receptor